Recursion is advancing REC-617, a promising reversible, non-covalent CDK7 inhibitor, showing potential in treating advanced ...

Incyclix Bio, LLC, a next-generation cell cycle control company developing INX-315, a novel, potent and selective CDK2 inhibitor for the treatment of advanced and resistant cancer, today announced the ...